Tom Lue, MD

Urologist

Dr. Tom Lue is an internationally recognized expert in the treatment of male sexual dysfunction at UCSF Medical Center. In 1983, he was one of the first urologists in the country to offer penile injection for erectile dysfunction. His research team proved that a new class of compound enhances erection in animals, which provided the scientific basis for three medications — Viagra, Levitra and Cialis, the most popular treatments for erectile dysfunction. Lue and his associates also developed the first animal model to study Peyronie's disease and introduced pentoxifylline for treatment.

Lue is vice chair of urology, medical director of the Knuppe Molecular Urology Laboratory and a professor of urology at UCSF. He graduated with highest honors from the Kaohsiung Medical College in Taiwan, completed urologic training at Downstate Medical Center in Brooklyn, N.Y. and was awarded the Valentine Fellowship from the New York Academy of Medicine to study the neurophysiology of the genitourinary tract at UCSF. He has won numerous awards, including the American Urological Association's Gold Cystoscope award and American Foundation of Urologic Disease's "Most Innovative Research Award." Lue has authored or co-authored more than 380 publications and 12 books on male sexual dysfunction.

Clinics

Urology Practice
400 Parnassus Ave., Sixth Floor, Suite A610
San Francisco, CA 94143
Phone: (415) 353-2200
Fax: (415) 353-2641

Hours: Monday to Friday
8 a.m. – 5 p.m.

Conditions & Treatments

Academic Title

Professor

More about Tom Lue

Additional Languages

Chinese

Education

Kaohsiung Medical College 1972

Residencies

SUNY Downstate Medical Center, Urology 1981

Fellowships

UCSF Medical Center, Urology

Selected Research and Publications

  1. Lue TF, Shindel AW. Five Things I Wish I Would Have Known Earlier in My Career: Lessons Learned in Peyronie's Disease Surgery. J Sex Med. 2018 May 31.
  2. Wang HS, Oh BS, Wang B, Ruan Y, Zhou J, Banie L, Lee YC, Tamaddon A, Tie Z, Wang G, Lin G, Lue TF. Low-Intensity Extracorporeal Shock Wave Therapy Ameliorates Diabetic Underactive Bladder in Streptozocin-Induced Diabetic Rats. BJU Int. 2018 Mar 30.
  3. Ruan Y, Zhou J, Kang N, Reed-Maldonado AB, Tamaddon A, Wang B, Wang HS, Wang G, Banie L, Lin G, Liu J, Lue TF. The Effect of Low-Intensity Extracorporeal Shock Wave Therapy in an Obesity-Associated Erectile Dysfunction Rat Model. BJU Int. 2018 Mar 23.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.